Adrian Preda

List of Publications by Year
in descending order

208 papers	20,664 citations	13098 68 h-index	11937 134 g-index
244 all docs	244 docs citations	244 times ranked	23157 citing authors

#	Article	IF	Citations
1	Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain, 2009, 132, 1355-1365.	7.6	975
2	Dynamic functional connectivity analysis reveals transient states of dysconnectivity in schizophrenia. NeuroImage: Clinical, 2014, 5, 298-308.	2.7	925
3	Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium. Molecular Psychiatry, 2016, 21, 547-553.	7.9	820
4	Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium. Biological Psychiatry, 2018, 84, 644-654.	1.3	627
5	Episodic memory loss is related to hippocampal-mediated Â-amyloid deposition in elderly subjects. Brain, 2009, 132, 1310-1323.	7.6	596
6	Identification of common variants associated with human hippocampal and intracranial volumes. Nature Genetics, 2012, 44, 552-561.	21.4	594
7	Widespread white matter microstructural differences in schizophrenia across 4322 individuals: results from the ENIGMA Schizophrenia DTI Working Group. Molecular Psychiatry, 2018, 23, 1261-1269.	7.9	522
8	Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis. American Journal of Psychiatry, 2006, 163, 790-799.	7.2	500
9	The genetic architecture of the human cerebral cortex. Science, 2020, 367, .	12.6	450
10	Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Brain Imaging and Behavior, 2012, 6, 502-516.	2.1	443
11	Altered bile acid profile associates with cognitive impairment in Alzheimer's disease—An emerging role for gut microbiome. Alzheimer's and Dementia, 2019, 15, 76-92.	0.8	396
12	A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging and Behavior, 2012, 6, 517-527.	2.1	371
13	Blood-Based Protein Biomarkers for Diagnosis of Alzheimer Disease. Archives of Neurology, 2012, 69, 1318.	4.5	348
14	GWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimer's Disease. Neuron, 2013, 78, 256-268.	8.1	344
15	Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort. NeuroImage, 2010, 53, 1051-1063.	4.2	340
16	Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia, 2019, 15, 106-152.	0.8	302
17	Working memory and DLPFC inefficiency in schizophrenia: The FBIRN study. Schizophrenia Bulletin, 2009, 35, 19-31.	4.3	300
18	Does feature selection improve classification accuracy? Impact of sample size and feature selection on classification using anatomical magnetic resonance images. NeuroImage, 2012, 60, 59-70.	4.2	281

#	Article	IF	Citations
19	Antidepressant-Associated Mania and Psychosis Resulting in Psychiatric Admissions. Journal of Clinical Psychiatry, 2001, 62, 30-33.	2.2	271
20	Multi-Method Analysis of MRI Images in Early Diagnostics of Alzheimer's Disease. PLoS ONE, 2011, 6, e25446.	2.5	240
21	Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE. Nature Communications, 2015, 6, 6760.	12.8	240
22	Voxelwise genome-wide association study (vGWAS). NeuroImage, 2010, 53, 1160-1174.	4.2	239
23	A commonly carried allele of the obesity-related *FTO* gene is associated with reduced brain volume in the healthy elderly. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 8404-8409.	7.1	227
24	Prediction of Alzheimer's disease in subjects with mild cognitive impairment from the ADNI cohort using patterns of cortical thinning. NeuroImage, 2013, 65, 511-521.	4.2	224
25	Gender Modulates the APOE Â4 Effect in Healthy Older Adults: Convergent Evidence from Functional Brain Connectivity and Spinal Fluid Tau Levels. Journal of Neuroscience, 2012, 32, 8254-8262.	3.6	222
26	Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional–executive network function in Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 10256-10261.	7.1	215
27	Function biomedical informatics research network recommendations for prospective multicenter functional MRI studies. Journal of Magnetic Resonance Imaging, 2012, 36, 39-54.	3.4	201
28	Subregional neuroanatomical change as a biomarker for Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 20954-20959.	7.1	198
29	Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers. Alzheimer's and Dementia, 2019, 15, 232-244.	0.8	198
30	Segmentation of MR images via discriminative dictionary learning and sparse coding: Application to hippocampus labeling. NeuroImage, 2013, 76, 11-23.	4.2	196
31	Discovering genetic associations with high-dimensional neuroimaging phenotypes: A sparse reduced-rank regression approach. NeuroImage, 2010, 53, 1147-1159.	4.2	186
32	Plasma Biomarkers Associated With the Apolipoprotein E Genotype and Alzheimer Disease. Archives of Neurology, 2012, 69, 1310.	4.5	186
33	Genome-wide association study of CSF biomarkers $A\beta_{1-42}$, t-tau, and p-tau$_{181p}$ in the ADNI cohort. Neurology, 2011, 76, 69-79.	1.1	185
34	MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults. Neurology, 2012, 78, 84-90.	1.1	184
35	Brain Changes in Older Adults at Very Low Risk for Alzheimer's Disease. Journal of Neuroscience, 2013, 33, 8237-8242.	3.6	184
36	Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology, 2011, 77, 1619-1628.	1.1	179

#	Article	IF	Citations
37	Predicting Alzheimer's disease progression using multi-modal deep learning approach. Scientific Reports, 2019, 9, 1952.	3.3	178
38	Standardization of analysis sets for reporting results from ADNI MRI data. Alzheimer's and Dementia, 2013, 9, 332-337.	0.8	172
39	QuickNAT: A fully convolutional network for quick and accurate segmentation of neuroanatomy. NeuroImage, 2019, 186, 713-727.	4.2	167
40	Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis. American Journal of Psychiatry, 2006, 163, 790.	7.2	157
41	Multi-source feature learning for joint analysis of incomplete multiple heterogeneous neuroimaging data. NeuroImage, 2012, 61, 622-632.	4.2	155
42	Longitudinal Change of Biomarkers in Cognitive Decline. Archives of Neurology, 2011, 68, 1257.	4.5	152
43	Higher Dimensional Meta-State Analysis Reveals Reduced Resting fMRI Connectivity Dynamism in Schizophrenia Patients. PLoS ONE, 2016, 11, e0149849.	2.5	148
44	Multi-modal imaging predicts memory performance in normal aging and cognitive decline. Neurobiology of Aging, 2010, 31, 1107-1121.	3.1	143
45	Genome-wide scan of healthy human connectome discovers <i>SPON1</i> gene variant influencing dementia severity. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 4768-4773.	7.1	141
46	The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. Schizophrenia Research, 2003, 61, 19-30.	2.0	138
47	Vascular burden and Alzheimer disease pathologic progression. Neurology, 2012, 79, 1349-1355.	1.1	138
48	Virtual Histology of Cortical Thickness and Shared Neurobiology in 6 Psychiatric Disorders. JAMA Psychiatry, 2021, 78, 47.	11.0	136
49	Increased power by harmonizing structural MRI site differences with the ComBat batch adjustment method in ENIGMA. NeuroImage, 2020, 218, 116956.	4.2	135
50	Multimodal neuromarkers in schizophrenia via cognition-guided MRI fusion. Nature Communications, 2018, 9, 3028.	12.8	127
51	Amyloid-Î²â€"Associated Clinical Decline Occurs Only in the Presence of Elevated P-tau. Archives of Neurology, 2012, 69, 709-13.	4.5	122
52	Sex-dependent association of common variants of microcephaly genes with brain structure. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 384-388.	7.1	118
53	The Alzheimer's Disease Assessment Scale-Cognitive-Plus (ADAS-Cog-Plus): an expansion of the ADAS-Cog to improve responsiveness in MCI. Brain Imaging and Behavior, 2012, 6, 489-501.	2.1	117
54	A robust method to estimate the intracranial volume across MRI field strengths (1.5T and 3T). NeuroImage, 2010, 50, 1427-1437.	4.2	116

#	Article	IF	Citations
55	Identifying disease sensitive and quantitative trait-relevant biomarkers from multidimensional heterogeneous imaging genetics data via sparse multimodal multitask learning. Bioinformatics, 2012, 28, i127-i136.	4.1	114
56	The Function Biomedical Informatics Research Network Data Repository. NeuroImage, 2016, 124, 1074-1079.	4.2	114
57	Alzheimer disease biomarkers are associated with body mass index. Neurology, 2011, 77, 1913-1920.	1.1	112
58	Converting positive and negative symptom scores between PANSS and SAPS/SANS. Schizophrenia Research, 2014, 152, 289-294.	2.0	111
59	Visual Hallucinations Are Associated With Hyperconnectivity Between the Amygdala and Visual Cortex in People With a Diagnosis of Schizophrenia. Schizophrenia Bulletin, 2015, 41, 223-232.	4.3	104
60	Tuning in to the Voices: A Multisite fMRI Study of Auditory Hallucinations. Schizophrenia Bulletin, 2009, 35, 58-66.	4.3	100
61	Genetic Variants in the Fat and Obesity Associated (FTO) Gene and Risk of Alzheimer's Disease. PLoS ONE, 2012, 7, e50354.	2.5	96
62	Impact of autocorrelation on functional connectivity. NeuroImage, 2014, 102, 294-308.	4.2	95
63	Rates of Decline in Alzheimer Disease Decrease with Age. PLoS ONE, 2012, 7, e42325.	2.5	89
64	Plasma Based Markers of [11C] PiB-PET Brain Amyloid Burden. PLoS ONE, 2012, 7, e44260.	2.5	89
65	Naming impairment in Alzheimer's disease is associated with left anterior temporal lobe atrophy. NeuroImage, 2012, 63, 348-355.	4.2	88
66	Resting-state thalamic dysconnectivity in schizophrenia and relationships with symptoms. Psychological Medicine, 2018, 48, 2492-2499.	4.5	86
67	Predicting the location of human perirhinal cortex, Brodmann's area 35, from MRI. NeuroImage, 2013, 64, 32-42.	4.2	81
68	Positive symptoms associate with cortical thinning in the superior temporal gyrus via the ENIGMA Schizophrenia consortium. Acta Psychiatrica Scandinavica, 2017, 135, 439-447.	4.5	80
69	Diffusion MRI Indices and Their Relation to Cognitive Impairment in Brain Aging: The Updated Multi-protocol Approach in ADNI3. Frontiers in Neuroinformatics, 2019, 13, 2.	2.5	79
70	Multivariate Protein Signatures of Pre-Clinical Alzheimer's Disease in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Plasma Proteome Dataset. PLoS ONE, 2012, 7, e34341.	2.5	73
71	Salienceâ€"Default Mode Functional Network Connectivity Linked to Positive and Negative Symptoms of Schizophrenia. Schizophrenia Bulletin, 2019, 45, 892-901.	4.3	71
72	Reduced sample sizes for atrophy outcomes in Alzheimer's disease trials: baseline adjustment. Neurobiology of Aging, 2010, 31, 1452-1462.e2.	3.1	70

#	Article	IF	Citations
73	Random forest prediction of Alzheimer's disease using pairwise selection from time series data. PLoS ONE, 2019, 14, e0211558.	2.5	70
74	Relating Intrinsic Low-Frequency BOLD Cortical Oscillations to Cognition in Schizophrenia. Neuropsychopharmacology, 2015, 40, 2705-2714.	5.4	68
75	Generative FDG-PET and MRI Model of Aging and Disease Progression in Alzheimer's Disease. PLoS Computational Biology, 2013, 9, e1002987.	3.2	67
76	The spatial chronnectome reveals a dynamic interplay between functional segregation and integration. Human Brain Mapping, 2019, 40, 3058-3077.	3.6	67
77	Voxel and surface-based topography of memory and executive deficits in mild cognitive impairment and Alzheimer's disease. Brain Imaging and Behavior, 2012, 6, 551-567.	2.1	66
78	Schizophrenia miR-137 Locus Risk Genotype Is Associated with Dorsolateral Prefrontal Cortex Hyperactivation. Biological Psychiatry, 2014, 75, 398-405.	1.3	65
79	Multimodal Fusion With Reference: Searching for Joint Neuromarkers of Working Memory Deficits in Schizophrenia. IEEE Transactions on Medical Imaging, 2018, 37, 93-105.	8.9	65
80	Confirmatory factor analysis of the ADNI neuropsychological battery. Brain Imaging and Behavior, 2012, 6, 528-539.	2.1	63
81	Extracting spurious messages from noise and risk of schizophrenia-spectrum disorders in a prodromal population. British Journal of Psychiatry, 2007, 191, 355-356.	2.8	62
82	Disease progression timeline estimation for Alzheimer's disease using discriminative event based modeling. NeuroImage, 2019, 186, 518-532.	4.2	61
83	Beta amyloid, tau, neuroimaging, and cognition: sequence modeling of biomarkers for Alzheimer's Disease. Brain Imaging and Behavior, 2012, 6, 610-620.	2.1	59
84	Genome-wide pathway analysis of memory impairment in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort implicates gene candidates, canonical pathways, and networks. Brain Imaging and Behavior, 2012, 6, 634-648.	2.1	58
85	Longitudinal change in neuropsychological performance using latent growth models: a study of mild cognitive impairment. Brain Imaging and Behavior, 2012, 6, 540-550.	2.1	53
86	Man Versus Machine: Comparison of Radiologists' Interpretations and NeuroQuant®Volumetric Analyses of Brain MRIs in Patients With Traumatic Brain Injury. Journal of Neuropsychiatry and Clinical Neurosciences, 2013, 25, 32-39.	1.8	53
87	Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease. Neurobiology of Aging, 2012, 33, 1599-1608.	3.1	52
88	Spatial dynamics within and between brain functional domains: A hierarchical approach to study time-varying brain function. Human Brain Mapping, 2019, 40, 1969-1986.	3.6	52
89	Predicting Short-term MCI-to-AD Progression Using Imaging, CSF, Genetic Factors, Cognitive Resilience, and Demographics. Scientific Reports, 2019, 9, 2235.	3.3	51
90	Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 3985-3990.	7.1	50

#	Article	IF	Citations
91	Analysis of Copy Number Variation in Alzheimer's Disease in a Cohort of Clinically Characterized and Neuropathologically Verified Individuals. PLoS ONE, 2012, 7, e50640.	2.5	49
92	White matter in different regions evolves differently during progression to dementia. Neurobiology of Aging, 2019, 76, 71-79.	3.1	49
93	Accurate risk estimation of Î²â€‘amyloid positivity to identify prodromal Alzheimer's disease: Crossâ€‑validation study of practical algorithms. Alzheimer's and Dementia, 2019, 15, 194-204.	0.8	49
94	Relationship between baseline brain metabolism measured using [18F]FDG PET and memory and executive function in prodromal and early Alzheimer's disease. Brain Imaging and Behavior, 2012, 6, 568-583.	2.1	47
95	CSF biomarker associations with change in hippocampal volume and precuneus thickness: implications for the Alzheimer's pathological cascade. Brain Imaging and Behavior, 2012, 6, 599-609.	2.1	46
96	Improved Classification of Alzheimer's Disease Data via Removal of Nuisance Variability. PLoS ONE, 2012, 7, e31112.	2.5	46
97	Dual-Model Radiomic Biomarkers Predict Development of Mild Cognitive Impairment Progression to Alzheimer's Disease. Frontiers in Neuroscience, 2018, 12, 1045.	2.8	46
98	Cortical thickness atrophy in the transentorhinal cortex in mild cognitive impairment. NeuroImage: Clinical, 2019, 21, 101617.	2.7	46
99	Neuropsychological profile in adult schizophrenia measured with the CMINDS. Psychiatry Research, 2015, 230, 826-834.	3.3	45
100	Fat-mass-related hormone, plasma leptin, predicts brain volumes in the elderly. NeuroReport, 2013, 24, 58-62.	1.2	43
101	The use of referenced-EEG (rEEG) in assisting medication selection for the treatment of depression. Journal of Psychiatric Research, 2011, 45, 64-75.	3.1	42
102	Identifying Cognitively Healthy Elderly Individuals with Subsequent Memory Decline by Using Automated MR Temporoparietal Volumes. Radiology, 2011, 259, 844-851.	7.3	42
103	Aberrant Dynamic Functional Connectivity of Default Mode Network in Schizophrenia and Links to Symptom Severity. Frontiers in Neural Circuits, 2021, 15, 649417.	2.8	42
104	Fast Identification of Biological Pathways Associated with a Quantitative Trait Using Group Lasso with Overlaps. Statistical Applications in Genetics and Molecular Biology, 2012, 11, 1-43.	0.6	41
105	Design and Application of a Generic Clinical Decision Support System for Multiscale Data. IEEE Transactions on Biomedical Engineering, 2012, 59, 234-240.	4.2	40
106	Classification of Structural MRI Images in Alzheimer's Disease from the Perspective of Ill-Posed Problems. PLoS ONE, 2012, 7, e44877.	2.5	40
107	A multi-scanner study of subcortical brain volume abnormalities in schizophrenia. Psychiatry Research - Neuroimaging, 2014, 222, 10-16.	1.8	39
108	Neural Correlates of Schizophrenia Negative Symptoms: Distinct Subtypes Impact Dissociable Brain Circuits. Molecular Neuropsychiatry, 2015, 1, 191-200.	2.9	39

#	Article	IF	Citations
109	A <scp>meta‑analysis</scp> of deep brain structural shape and asymmetry abnormalities in 2,833 individuals with schizophrenia compared with 3,929 healthy volunteers via the <scp>ENIGMA Consortium</scp>. Human Brain Mapping, 2022, 43, 352-372.	3.6	39
110	Predicting missing biomarker data in a longitudinal study of Alzheimer disease. Neurology, 2012, 78, 1376-1382.	1.1	38
111	Modality-Dependent Impact of Hallucinations on Low-Frequency Fluctuations in Schizophrenia. Schizophrenia Bulletin, 2017, 43, sbw093.	4.3	37
112	Improved inference in Bayesian segmentation using Monte Carlo sampling: Application to hippocampal subfield volumetry. Medical Image Analysis, 2013, 17, 766-778.	11.6	36
113	Treatment Histories of Patients With a Syndrome Putatively Prodromal to Schizophrenia. Psychiatric Services, 2002, 53, 342-344.	2.0	34
114	Functional signature of conversion of patients with mild cognitive impairment. Neurobiology of Aging, 2019, 74, 21-37.	3.1	34
115	Informed Consent: How Much Awareness Is There?. PLoS ONE, 2014, 9, e110139.	2.5	34
116	Medical Image Imputation From Image Collections. IEEE Transactions on Medical Imaging, 2019, 38, 504-514.	8.9	33
117	Predicting AD Conversion: Comparison between Prodromal AD Guidelines and Computer Assisted PredictAD Tool. PLoS ONE, 2013, 8, e55246.	2.5	31
118	A safety evaluation of aripiprazole in the treatment of schizophrenia. Expert Opinion on Drug Safety, 2020, 19, 1529-1538.	2.4	31
119	Lamotrigine as Prophylaxis Against Steroid-Induced Mania. Journal of Clinical Psychiatry, 1999, 60, 708-709.	2.2	30
120	Disrupted network cross talk, hippocampal dysfunction and hallucinations in schizophrenia. Schizophrenia Research, 2018, 199, 226-234.	2.0	29
121	Next Generation Sequencing Analysis in Early Onset Dementia Patients. Journal of Alzheimer's Disease, 2019, 67, 243-256.	2.6	29
122	Multi-spatial-scale dynamic interactions between functional sources reveal sex-specific changes in schizophrenia. Network Neuroscience, 2022, 6, 357-381.	2.6	29
123	A review of statistical methods in imaging genetics. Canadian Journal of Statistics, 2019, 47, 108-131.	0.9	27
124	Communicability disruption in Alzheimer's disease connectivity networks. Journal of Complex Networks, 2019, 7, 83-100.	1.8	26
125	A concise and persistent feature to study brain resting‑state network dynamics: Findings from the Alzheimer's Disease Neuroimaging Initiative. Human Brain Mapping, 2019, 40, 1062-1081.	3.6	26
126	Decreased hemispheric connectivity and decreased intra- and inter- hemisphere asymmetry of resting state functional network connectivity in schizophrenia. Brain Imaging and Behavior, 2018, 12, 615-630.	2.1	25

#	ARTICLE	IF	CITATIONS
127	Translating Alzheimer's disease–associated polymorphisms into functional candidates: a survey of IGAP genes and SNPs. Neurobiology of Aging, 2019, 74, 135-146.	3.1	25
128	Multiple overlapping dynamic patterns of the visual sensory network in schizophrenia. Schizophrenia Research, 2021, 228, 103-111.	2.0	25
129	Reward Processing in Novelty Seekers: A Transdiagnostic Psychiatric Imaging Biomarker. Biological Psychiatry, 2021, 90, 529-539.	1.3	25
130	Cortical signatures of cognition and their relationship to Alzheimer's disease. Brain Imaging and Behavior, 2012, 6, 584-598.	2.1	24
131	Longitudinal Functional Brain Mapping in Supernormals. Cerebral Cortex, 2019, 29, 242-252.	2.9	24
132	Prognosis of conversion of mild cognitive impairment to Alzheimer's dementia by voxel-wise Cox regression based on FDG PET data. NeuroImage: Clinical, 2019, 21, 101637.	2.7	24
133	A framework for linking resting-state chronnectome/genome features in schizophrenia: A pilot study. NeuroImage, 2019, 184, 843-854.	4.2	24
134	Empirical derivation of the reference region for computing diagnostic sensitive 18fluorodeoxyglucose ratios in Alzheimer's disease based on the ADNI sample. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 457-466.	3.8	23
135	Parallel group ICA+ICA: Joint estimation of linked functional network variability and structural covariation with application to schizophrenia. Human Brain Mapping, 2019, 40, 3795-3809.	3.6	23
136	Genetic architecture of resilience of executive functioning. Brain Imaging and Behavior, 2012, 6, 621-633.	2.1	22
137	Structural Brain Alterations before Mild Cognitive Impairment in ADNI: Validation of Volume Loss in a Predefined Antero-Temporal Region. Journal of Alzheimer's Disease, 2012, 31, S49-S58.	2.6	22
138	Weighted average of shared trajectory: A new estimator for dynamic functional connectivity efficiently estimates both rapid and slow changes over time. Journal of Neuroscience Methods, 2020, 334, 108600.	2.5	22
139	A blood-based signature of cerebrospinal fluid Aβ1–42 status. Scientific Reports, 2019, 9, 4163.	3.3	21
140	Semi-Supervised Multimodal Relevance Vector Regression Improves Cognitive Performance Estimation from Imaging and Biological Biomarkers. Neuroinformatics, 2013, 11, 339-353.	2.8	20
141	The Receiver Operational Characteristic for Binary Classification with Multiple Indices and Its Application to the Neuroimaging Study of Alzheimer's Disease. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2013, 10, 173-180.	3.0	20
142	Predicting brain activity using a Bayesian spatial model. Statistical Methods in Medical Research, 2013, 22, 382-397.	1.5	20
143	D$_2$receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder. CNS Spectrums, 2014, 19, 176-181.	1.2	20
144	Accuracy and generalization capability of an automatic method for the detection of typical brain hypometabolism in prodromal Alzheimer disease. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 334-347.	6.4	20

#	Article	IF	Citations
145	MRI Monitoring of Tumor Response to a Novel VEGF Tyrosine Kinase Inhibitor in an Experimental Breast Cancer Model. Academic Radiology, 2002, 9, S519-S520.	2.5	19
146	Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimer's disease. NeuroReport, 2010, 21, 802-807.	1.2	19
147	Functional activity maps based on significance measures and Independent Component Analysis. Computer Methods and Programs in Biomedicine, 2013, 111, 255-268.	4.7	19
148	Evaluating trajectories of episodic memory in normal cognition and mild cognitive impairment: Results from ADNI. PLoS ONE, 2019, 14, e0212435.	2.5	19
149	Characterizing Whole Brain Temporal Variation of Functional Connectivity via Zero and First Order Derivatives of Sliding Window Correlations. Frontiers in Neuroscience, 2019, 13, 634.	2.8	17
150	Moving beyond the 'CAP' of the Iceberg: Intrinsic connectivity networks in fMRI are continuously engaging and overlapping. NeuroImage, 2022, 251, 119013.	4.2	17
151	Dysexecutive and amnesic AD subtypes defined by single indicator and modern psychometric approaches: relationships with SNPs in ADNI. Brain Imaging and Behavior, 2012, 6, 649-660.	2.1	16
152	Longitudinal Brain Atrophy Rates in Transient Ischemic Attack and Minor Ischemic Stroke Patients and Cognitive Profiles. Frontiers in Neurology, 2019, 10, 18.	2.4	15
153	Validation of ketamine as a pharmacological model of thalamic dysconnectivity across the illness course of schizophrenia. Molecular Psychiatry, 2022, 27, 2448-2456.	7.9	15
154	Plasma catecholamine metabolites in antidepressant-exacerbated mania and psychosis. Journal of Affective Disorders, 2002, 68, 331-334.	4.1	14
155	Multidimensional frequency domain analysis of full-volume fMRI reveals significant effects of age, gender, and mental illness on the spatiotemporal organization of resting-state brain activity. Frontiers in Neuroscience, 2015, 9, 203.	2.8	14
156	Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia. Expert Opinion on Pharmacotherapy, 2016, 17, 395-407.	1.8	13
157	Fast Multi-Task SCCA Learning with Feature Selection for Multi-Modal Brain Imaging Genetics. , 2018, 2018, 356-361.		13
158	P.1.e.028 Dopamine D3 and D2 receptor occupancy of cariprazine in schizophrenic patients. European Neuropsychopharmacology, 2009, 19, S316.	0.7	12
159	A Novel Method to Estimate Long-Term Chronological Changes From Fragmented Observations in Disease Progression. Clinical Pharmacology and Therapeutics, 2019, 105, 436-447.	4.7	12
160	Robust Motion Regression of Resting-State Data Using a Convolutional Neural Network Model. Frontiers in Neuroscience, 2019, 13, 169.	2.8	12
161	Autoconnectivity: A new perspective on human brain function. Journal of Neuroscience Methods, 2019, 323, 68-76.	2.5	12
162	Oxytocin Enhances an Amygdala Circuit Associated With Negative Symptoms in Schizophrenia: A Single-Dose, Placebo-Controlled, Crossover, Randomized Control Trial. Schizophrenia Bulletin, 2020, 46, 661-669.	4.3	12

#	ARTICLE	IF	CITATIONS
163	Association of CSF CD40 levels and synaptic degeneration across the Alzheimer's disease spectrum. Neuroscience Letters, 2019, 694, 41-45.	2.1	11
164	Nonlinear functional network connectivity in resting functional magnetic resonance imaging data. Human Brain Mapping, 2022, 43, 4556-4566.	3.6	11
165	Magnetic Resonance Imaging of Liver Lesions: Exceptions and Atypical Lesions. Current Problems in Diagnostic Radiology, 2008, 37, 95-103.	1.4	10
166	Integrating semi-supervised label propagation and random forests for multi-atlas based hippocampus segmentation. , 2018, 2018, 154-157.		10
167	aBEAT: A Toolbox for Consistent Analysis of Longitudinal Adult Brain MRI. PLoS ONE, 2013, 8, e60344.	2.5	9
168	Meta-Modal Information Flow: A Method for Capturing Multimodal Modular Disconnectivity in Schizophrenia. IEEE Transactions on Biomedical Engineering, 2020, 67, 2572-2584.	4.2	9
169	MAPT rs242557 variant is associated with hippocampus tau uptake on 18F-AV-1451 PET in non-demented elders. Aging, 2019, 11, 874-884.	3.1	9
170	Predictive Factors for Natural Pregnancy after Microsurgical Reconstruction in Patients with Primary Epididymal Obstructive Azoospermia. International Journal of Endocrinology, 2014, 2014, 1-6.	1.5	8
171	A Î´ Homolog for Dementia Case Finding with Replication in the Alzheimer's Disease Neuroimaging Initiative. Journal of Alzheimer's Disease, 2019, 67, 67-79.	2.6	8
172	Multi-model Order ICA: A Data-driven Method for Evaluating Brain Functional Network Connectivity Within and Between Multiple Spatial Scales. Brain Connectivity, 2021, , .	1.7	7
173	Predicting progressions of cognitive outcomes via high-order multi-modal multi-task feature learning. , 2018, , .		6
174	Altered Domain Functional Network Connectivity Strength and Randomness in Schizophrenia. Frontiers in Psychiatry, 2019, 10, 499.	2.6	6
175	Amyloid beta–positive subjects exhibit longitudinal network-specific reductions in spontaneous brain activity. Neurobiology of Aging, 2019, 74, 191-201.	3.1	6
176	Covarying structural alterations in laterality of the temporal lobe in schizophrenia: A case for source‐based laterality. NMR in Biomedicine, 2020, 33, e4294.	2.8	6
177	Quality Assurance in Functional MRI. Biological Magnetic Resonance, 2015, , 245-270.	0.4	6
178	Multiple incomplete views clustering via non-negative matrix factorization with its application in Alzheimer's disease analysis. , 2018, , .		5
179	Reply to: New Meta- and Mega-analyses of Magnetic Resonance Imaging Findings in Schizophrenia: Do They Really Increase Our Knowledge About the Nature of the Disease Process?. Biological Psychiatry, 2019, 85, e35-e39.	1.3	5
180	ENIGMA‰+‰COINSTAC: Improving Findability, Accessibility, Interoperability, and Re-usability. Neuroinformatics, 2022, 20, 261-275.	2.8	5

#	Article	IF	Citations
181	Supervised multimodal fusion and its application in searching joint neuromarkers of working memory deficits in schizophrenia. , 2016, 2016, 4021-4026.		4
182	PREMATURE POLYPSYCHOPHARMACOLOGY. Journal of the American Academy of Child and Adolescent Psychiatry, 1998, 37, 348-349.	0.5	3
183	Review: Antipsychotic drugs improve symptoms, with different levels of side effects, in schizophrenia. Annals of Internal Medicine, 2013, 159, JC7.	3.9	3
184	A positive take on schizophrenia negative symptom scales: Converting scores between the SANS, NSA and SDS. Schizophrenia Research, 2018, 201, 113-119.	2.0	3
185	Course of Schizophrenia: What Has Been Learned from Longitudinal Studies?. , 2011, , 281-300.		3
186	Time-varying Graphs: A Method to Identify Abnormal Integration and Disconnection in Functional Brain Connectivity with Application to Schizophrenia. , 2020, , .		3
187	Bypassing Shame and Conversion Disorder. CNS Spectrums, 2010, 15, 607-611.	1.2	2
188	Review: Lithium is associated with adverse events in patients with mood disorders. Annals of Internal Medicine, 2012, 157, JC1.	3.9	2
189	Functional Magnetic Resonance Imaging of Motor Cortex Activation in Schizophrenia. Journal of Korean Medical Science, 2015, 30, 625.	2.5	2
190	No health without mental health. Mental Illness, 2016, 8, 6609.	0.8	2
191	Brain Density Clustering Analysis: A New Approach to Brain Functional Dynamics. Frontiers in Neuroscience, 2021, 15, 621716.	2.8	2
192	Converting scores between the PANSS and SAPS/SANS beyond the positive/negative dichotomy. Psychiatry Research, 2021, 305, 114199.	3.3	2
193	Path analysis: A method to estimate altered pathways in time-varying graphs of neuroimaging data. Network Neuroscience, 2022, 6, 634-664.	2.6	2
194	Longitudinal Course of Schizophrenia. Current Psychiatry Reviews, 2011, 7, 205-216.	0.9	1
195	A method for building a genome-connectome bipartite graph model. Journal of Neuroscience Methods, 2019, 320, 64-71.	2.5	1
196	Neurocognitive Deficits, Negative Symptoms, and Insight in Schizophrenia. , 2011, , 33-74.		1
197	Brain Imaging Correlates of Anhedonia. , 2014, , 331-341.		1
198	Do Schizophrenia Patients Want to Be Involved in Their Treatment?. American Journal of Psychiatry, 2006, 163, 937-937.	7.2	0

#	Article	IF	Citations
199	Bypassing Shame and Conversion Disorder. European Psychiatry, 2009, 24, .	0.2	0
200	The Self and Asperger Syndrome. Southern Medical Journal, 2011, 104, 250-251.	0.7	0
201	Urological Complications in Kidney Retransplanted Patients - A Single Centre Experience.. Transplantation, 2014, 98, 645-646.	1.0	0
202	DYNAMICS OF INTRINSIC CONNECTIVITY NETWORKS IN SCHIZOPHRENIA. Schizophrenia Research, 2014, 153, S12-S13.	2.0	0
203	Polyomavirus BK-Associated Nephropathy After Kidney Transplantation. Transplantation, 2018, 102, S567.	1.0	0
204	Sponsored Clinical Trials and Bias. Journal of Clinical Psychiatry, 2007, 68, 1621-1622.	2.2	0
205	Shared Decision Making in Schizophrenia Treatment. Journal of Clinical Psychiatry, 2008, 69, 326.	2.2	0
206	Using New Antipsychotics in Your Clinical Practice. Journal of Clinical Psychiatry, 2010, 71, e101.	2.2	0
207	Building Models of Functional Interactions Among Brain Domains that Encode Varying Information Complexity: A Schizophrenia Case Study. Neuroinformatics, 2022, 20, 777-791.	2.8	0
208	Do Schizophrenia Patients Want to Be Involved in Their Treatment?. American Journal of Psychiatry, 2006, 163, 937-937.	7.2	0